Discovery of ferulic acid carbamate derivatives as dual-targeting agents of BuChE and Nrf2 for Alzheimer’s disease

Read full text Summarise with VIRAT
Authors: Kejing Lao, Yingze Li, Yueyan Xiao, Ya Nan Sun, Yuxuan Dai, Huijin Li, Yang Yang, Yun Zhang, Jing Wang, Weize Li, Xingchun Gou, Li Guan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Given the multifactorial aetiology of Alzheimer’s disease, multi-target strategies have emerged as a promising therapeutic approach. In this study, we designed and synthesised a series of ferulic acid carbamate derivatives to selectively inhibit BuChE and stimulate Nrf2 pathway. The biological evaluation revealed that compound 5c and 5e were the most potent, exhibiting over 150-fold selectivity for BuChE. Also, 5c, 5g and 5h significantly reversed both H2O2− and Aβ-induced toxicity in HT22 cells. These compounds were further shown to eliminate ROS accumulation induced by Aβ and upregulated HO-1 and GCLM by promoting the nuclei translocation of Nrf2. In Aβ transgenic C. elegans, three lead compounds alleviated Aβ-induced paralysis and cognitive deficits. In silico study revealed that compound 5c fitted well into the active sites of BuChE and Keap1 while maintaining favourable CNS drugability. This dual strategy of cholinesterase inhibition and oxidative stress mitigation is a promising approach for novel AD therapeutics.

Fields of Study & Subjects

Cholinesterase and Neurodegenerative Diseases Alzheimer's disease research and treatments Heterocyclic Compound Synthesis and Bioactivity

Publication details

Journal / source
Figshare
Publication date
31 March 2026
Language
EN